Alexandria Real Estate Equities Honored with 2025 Partnership Award for Addressing Depression

Alexandria Real Estate Equities Receives Prestigious Award

On October 22, 2025, Alexandria Real Estate Equities, Inc. made headlines by being awarded the 2025 Charles A. Sanders, MD, Partnership Award from the Foundation for the National Institutes of Health (FNIH). This honor is a testament to Alexandria's impactful role in the realm of biomedical innovation, particularly its leadership in establishing a crucial public-private partnership aimed at transforming depression treatment through precision medicine.

Based in Pasadena, California, Alexandria is renowned as a pioneering entity in the life science real estate sector, manipulating mega-campus ecosystems that support scientific advancement. The FNIH award acknowledges Alexandria's vision and leadership in addressing some of the most pressing health crises of our time. Specifically, it highlights their efforts to reform the treatment landscape for major depressive disorder (MDD), a condition that impacts over 21 million adults in the United States annually, with nearly one-third enduring treatment-resistant depression.

During the award ceremony held in Washington, D.C., Joel S. Marcus, the executive chairman and founder of Alexandria, expressed gratitude and pride in their significant contributions to improving mental health care. He emphasized that the costs associated with MDD are staggering, posing an economic burden exceeding $380 billion annually, which has made it imperative to discover and implement innovative treatment solutions.

Alexandria's initiative, dubbed the Multi-Level Assessment Phenotyping in Depression (MAP-D), aims to foster comprehensive and collaborative research that will pave the way for the development of effective treatments. This project has garnered support from notable institutions, including the National Institute of Mental Health, the U.S. Food and Drug Administration, and the U.S. Department of Veterans Affairs. Furthermore, the initiative collaborates with leading research organizations and patient advocates.

The MAP-D program is currently in its design phase, and its comprehensive clinical study is set to launch by May 2026, aiming to coincide with Mental Health Awareness Month. This study will focus on identifying and validating biomarkers that can lead to tailored depression treatments, moving away from a generic